Eupraxia Pharmaceuticals (EPRX) Projected to Release Quarterly Earnings on Tuesday

Key Points

• Eupraxia Pharmaceuticals is expected to report Q3 2026 results before the market opens on November 3, with analysts forecasting a loss of $0.26 per share. Its earnings conference call is scheduled for November 5 at 4:00 p.m. ET.
• The company reported a better-than-expected loss of $0.23 per share in the previous quarter, compared with the consensus estimate of a $0.25 loss. Analysts project losses of $0.85 per share for the current fiscal year and $0.99 for the next.
• Analyst sentiment is mixed but leans positive, with a consensus “Moderate Buy” rating and a $17.80 target price versus the stock’s recent price of $6.85. Eupraxia is a clinical-stage biopharmaceutical company developing locally delivered therapies, including its lead osteoarthritis treatment candidate EP-262.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.26) per share for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. On average, analysts expect Eupraxia Pharmaceuticals to post ($0.85) EPS for the current fiscal year and ($0.99) EPS for the next fiscal year.

Eupraxia Pharmaceuticals Price Performance

Eupraxia Pharmaceuticals stock opened at $6.85 on Tuesday. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average of $7.57 and a 200-day moving average of $7.34. Eupraxia Pharmaceuticals has a 52 week low of $5.25 and a 52 week high of $9.32.

Analyst Ratings Changes

A number of brokerages recently issued reports on EPRX. Wall Street Zen lowered shares of Eupraxia Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, October 17th. Cantor Fitzgerald reissued an "overweight" rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 15th. HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 1st. Finally, Oppenheimer restated an "outperform" rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, October 20th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $17.80.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability.

Eupraxia's lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.